CDC37

Across TCGA pan-cancer cohorts, CDC37 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDC37 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDC37 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDC37 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where CDC37 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.857	0.413	.004	12	view →
LSCC	DFS	Tertile	All	1.000	0.388	.008	11	view →
LUAD	OS	Median	All	0.757	0.892	.039	3	view →
HNSC	DFS	Tertile	III,IV	0.708	0.866	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDC37–PDAC (DFS)

Open the PDAC breakdown →